NRG
AKBA icon

Nemes Rush Group’s Akebia Therapeutics AKBA Stock Holding History

Nemes Rush Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3 Buy
+2
New +$3 ﹤0.01% 943

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nemes Rush Group's AKBA Position: Q1 2026 in Review

Nemes Rush Group opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #943 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Nemes Rush Group held 2 shares of Akebia Therapeutics worth $3 as of Q1 2026.
  • Akebia Therapeutics was a new Nemes Rush Group position in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #943 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.